Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa

Myron J J Levin, Jane C C Lindsey, Susan S S Kaplan, Werner Schimana, Jody Lawrence, Monica M M McNeal, Mutsa Bwakura-Dangarembizi, Anthony Ogwu, Evans M M Mpabalwani, Paul Sato, George Siberry, Margaret Nelson, Darcy Hille, Geoffrey A A Weinberg, Adriana Weinberg

Research output: Contribution to journalArticle

Abstract

OBJECTIVE:: Although many HIV-infected (HIV+) and HIV-exposed but uninfected (HEU) infants have received live rotavirus vaccines since the World Health Organization recommended universal administration of these vaccines to infants, there has been limited prospective information on their safety and immunogenicity in either group of infants. DESIGN/METHODS:: We performed a randomized, double-blinded, placebo-controlled trial of the safety and immunogenicity of oral pentavalent rotavirus vaccine (RV5) administered to HIV+ and HEU infants in 4 African countries. Ninety-three % of HIV+ infants were receiving antiretroviral therapy prior to vaccination. Participants were followed for safety. Immune responses were measured 14 days after three doses of RV5, including serum anti-rotavirus neutralizing and IgA antibodies; IgA antibody in stool; and anti-rotavirus memory B- and T-cell Fluorospot. Shedding of RV5 in stool was monitored. RESULTS:: 76 HIV+ and 126 HEU infants were enrolled from 2009–2013. No significant differences were found in adverse event rates, including grade 3 events, between RV5 and placebo recipients, for either HIV+ or HEU infants. The proportion of anti-rotavirus IgA responders (≥3-fold increase from baseline) after RV5 administration was 81% in both HIV+ and HEU infants, which was approximately 2.5-fold higher than in placebo recipients (p?<?0.001). Neutralizing antibody responses to 3 of 5 serotypes were significantly higher after RV5 regardless of HIV status, and those of HIV+ infants were equal or greater than responses of HEU infants to all 5 serotypes. Only one HIV+ RV5 recipient had RV5 isolated from stool. CONCLUSION:: RV5 was immunogenic in both HIV+ and HEU infants and no safety signals were observed.

Original languageEnglish (US)
JournalAIDS
DOIs
StateAccepted/In press - Sep 20 2016
Externally publishedYes

Fingerprint

Rotavirus Vaccines
HIV Infections
HIV
Safety
Rotavirus
Placebos
Neutralizing Antibodies
Immunoglobulin A

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Levin, M. J. J., Lindsey, J. C. C., Kaplan, S. S. S., Schimana, W., Lawrence, J., McNeal, M. M. M., ... Weinberg, A. (Accepted/In press). Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa. AIDS. https://doi.org/10.1097/QAD.0000000000001258

Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa. / Levin, Myron J J; Lindsey, Jane C C; Kaplan, Susan S S; Schimana, Werner; Lawrence, Jody; McNeal, Monica M M; Bwakura-Dangarembizi, Mutsa; Ogwu, Anthony; Mpabalwani, Evans M M; Sato, Paul; Siberry, George; Nelson, Margaret; Hille, Darcy; Weinberg, Geoffrey A A; Weinberg, Adriana.

In: AIDS, 20.09.2016.

Research output: Contribution to journalArticle

Levin, MJJ, Lindsey, JCC, Kaplan, SSS, Schimana, W, Lawrence, J, McNeal, MMM, Bwakura-Dangarembizi, M, Ogwu, A, Mpabalwani, EMM, Sato, P, Siberry, G, Nelson, M, Hille, D, Weinberg, GAA & Weinberg, A 2016, 'Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa', AIDS. https://doi.org/10.1097/QAD.0000000000001258
Levin, Myron J J ; Lindsey, Jane C C ; Kaplan, Susan S S ; Schimana, Werner ; Lawrence, Jody ; McNeal, Monica M M ; Bwakura-Dangarembizi, Mutsa ; Ogwu, Anthony ; Mpabalwani, Evans M M ; Sato, Paul ; Siberry, George ; Nelson, Margaret ; Hille, Darcy ; Weinberg, Geoffrey A A ; Weinberg, Adriana. / Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa. In: AIDS. 2016.
@article{417a2166387945b995345bc3b415134a,
title = "Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa",
abstract = "OBJECTIVE:: Although many HIV-infected (HIV+) and HIV-exposed but uninfected (HEU) infants have received live rotavirus vaccines since the World Health Organization recommended universal administration of these vaccines to infants, there has been limited prospective information on their safety and immunogenicity in either group of infants. DESIGN/METHODS:: We performed a randomized, double-blinded, placebo-controlled trial of the safety and immunogenicity of oral pentavalent rotavirus vaccine (RV5) administered to HIV+ and HEU infants in 4 African countries. Ninety-three {\%} of HIV+ infants were receiving antiretroviral therapy prior to vaccination. Participants were followed for safety. Immune responses were measured 14 days after three doses of RV5, including serum anti-rotavirus neutralizing and IgA antibodies; IgA antibody in stool; and anti-rotavirus memory B- and T-cell Fluorospot. Shedding of RV5 in stool was monitored. RESULTS:: 76 HIV+ and 126 HEU infants were enrolled from 2009–2013. No significant differences were found in adverse event rates, including grade 3 events, between RV5 and placebo recipients, for either HIV+ or HEU infants. The proportion of anti-rotavirus IgA responders (≥3-fold increase from baseline) after RV5 administration was 81{\%} in both HIV+ and HEU infants, which was approximately 2.5-fold higher than in placebo recipients (p?<?0.001). Neutralizing antibody responses to 3 of 5 serotypes were significantly higher after RV5 regardless of HIV status, and those of HIV+ infants were equal or greater than responses of HEU infants to all 5 serotypes. Only one HIV+ RV5 recipient had RV5 isolated from stool. CONCLUSION:: RV5 was immunogenic in both HIV+ and HEU infants and no safety signals were observed.",
author = "Levin, {Myron J J} and Lindsey, {Jane C C} and Kaplan, {Susan S S} and Werner Schimana and Jody Lawrence and McNeal, {Monica M M} and Mutsa Bwakura-Dangarembizi and Anthony Ogwu and Mpabalwani, {Evans M M} and Paul Sato and George Siberry and Margaret Nelson and Darcy Hille and Weinberg, {Geoffrey A A} and Adriana Weinberg",
year = "2016",
month = "9",
day = "20",
doi = "10.1097/QAD.0000000000001258",
language = "English (US)",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa

AU - Levin, Myron J J

AU - Lindsey, Jane C C

AU - Kaplan, Susan S S

AU - Schimana, Werner

AU - Lawrence, Jody

AU - McNeal, Monica M M

AU - Bwakura-Dangarembizi, Mutsa

AU - Ogwu, Anthony

AU - Mpabalwani, Evans M M

AU - Sato, Paul

AU - Siberry, George

AU - Nelson, Margaret

AU - Hille, Darcy

AU - Weinberg, Geoffrey A A

AU - Weinberg, Adriana

PY - 2016/9/20

Y1 - 2016/9/20

N2 - OBJECTIVE:: Although many HIV-infected (HIV+) and HIV-exposed but uninfected (HEU) infants have received live rotavirus vaccines since the World Health Organization recommended universal administration of these vaccines to infants, there has been limited prospective information on their safety and immunogenicity in either group of infants. DESIGN/METHODS:: We performed a randomized, double-blinded, placebo-controlled trial of the safety and immunogenicity of oral pentavalent rotavirus vaccine (RV5) administered to HIV+ and HEU infants in 4 African countries. Ninety-three % of HIV+ infants were receiving antiretroviral therapy prior to vaccination. Participants were followed for safety. Immune responses were measured 14 days after three doses of RV5, including serum anti-rotavirus neutralizing and IgA antibodies; IgA antibody in stool; and anti-rotavirus memory B- and T-cell Fluorospot. Shedding of RV5 in stool was monitored. RESULTS:: 76 HIV+ and 126 HEU infants were enrolled from 2009–2013. No significant differences were found in adverse event rates, including grade 3 events, between RV5 and placebo recipients, for either HIV+ or HEU infants. The proportion of anti-rotavirus IgA responders (≥3-fold increase from baseline) after RV5 administration was 81% in both HIV+ and HEU infants, which was approximately 2.5-fold higher than in placebo recipients (p?<?0.001). Neutralizing antibody responses to 3 of 5 serotypes were significantly higher after RV5 regardless of HIV status, and those of HIV+ infants were equal or greater than responses of HEU infants to all 5 serotypes. Only one HIV+ RV5 recipient had RV5 isolated from stool. CONCLUSION:: RV5 was immunogenic in both HIV+ and HEU infants and no safety signals were observed.

AB - OBJECTIVE:: Although many HIV-infected (HIV+) and HIV-exposed but uninfected (HEU) infants have received live rotavirus vaccines since the World Health Organization recommended universal administration of these vaccines to infants, there has been limited prospective information on their safety and immunogenicity in either group of infants. DESIGN/METHODS:: We performed a randomized, double-blinded, placebo-controlled trial of the safety and immunogenicity of oral pentavalent rotavirus vaccine (RV5) administered to HIV+ and HEU infants in 4 African countries. Ninety-three % of HIV+ infants were receiving antiretroviral therapy prior to vaccination. Participants were followed for safety. Immune responses were measured 14 days after three doses of RV5, including serum anti-rotavirus neutralizing and IgA antibodies; IgA antibody in stool; and anti-rotavirus memory B- and T-cell Fluorospot. Shedding of RV5 in stool was monitored. RESULTS:: 76 HIV+ and 126 HEU infants were enrolled from 2009–2013. No significant differences were found in adverse event rates, including grade 3 events, between RV5 and placebo recipients, for either HIV+ or HEU infants. The proportion of anti-rotavirus IgA responders (≥3-fold increase from baseline) after RV5 administration was 81% in both HIV+ and HEU infants, which was approximately 2.5-fold higher than in placebo recipients (p?<?0.001). Neutralizing antibody responses to 3 of 5 serotypes were significantly higher after RV5 regardless of HIV status, and those of HIV+ infants were equal or greater than responses of HEU infants to all 5 serotypes. Only one HIV+ RV5 recipient had RV5 isolated from stool. CONCLUSION:: RV5 was immunogenic in both HIV+ and HEU infants and no safety signals were observed.

UR - http://www.scopus.com/inward/record.url?scp=84988650145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988650145&partnerID=8YFLogxK

U2 - 10.1097/QAD.0000000000001258

DO - 10.1097/QAD.0000000000001258

M3 - Article

C2 - 27662551

AN - SCOPUS:84988650145

JO - AIDS

JF - AIDS

SN - 0269-9370

ER -